BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 12888812)

  • 1. Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: a centre-based study of 17 patients.
    Bümming P; Andersson J; Meis-Kindblom JM; Klingenstierna H; Engström K; Stierner U; Wängberg B; Jansson S; Ahlman H; Kindblom LG; Nilsson B
    Br J Cancer; 2003 Aug; 89(3):460-4. PubMed ID: 12888812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations.
    Haller F; Detken S; Schulten HJ; Happel N; Gunawan B; Kuhlgatz J; Füzesi L
    Ann Surg Oncol; 2007 Feb; 14(2):526-32. PubMed ID: 17139461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response to imatinib mesylate of a gastrointestinal stromal tumor with very low expression of KIT.
    Bauer S; Corless CL; Heinrich MC; Dirsch O; Antoch G; Kanja J; Seeber S; Schütte J
    Cancer Chemother Pharmacol; 2003 Mar; 51(3):261-5. PubMed ID: 12655446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors.
    Chen LL; Trent JC; Wu EF; Fuller GN; Ramdas L; Zhang W; Raymond AK; Prieto VG; Oyedeji CO; Hunt KK; Pollock RE; Feig BW; Hayes KJ; Choi H; Macapinlac HA; Hittelman W; Velasco MA; Patel S; Burgess MA; Benjamin RS; Frazier ML
    Cancer Res; 2004 Sep; 64(17):5913-9. PubMed ID: 15342366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current clinical management of gastrointestinal stromal tumors.
    Tosoni A; Nicolardi L; Brandes AA
    Expert Rev Anticancer Ther; 2004 Aug; 4(4):595-605. PubMed ID: 15270663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acquired resistance to imatinib and secondary KIT exon 13 mutation in gastrointestinal stromal tumour.
    Bertucci F; Goncalves A; Monges G; Madroszyk A; Guiramand J; Moutardier V; Noguchi T; Dubreuil P; Sobol H
    Oncol Rep; 2006 Jul; 16(1):97-101. PubMed ID: 16786129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Late resistance to imatinib therapy in a metastatic gastrointestinal stromal tumour is associated with a second KIT mutation.
    Wakai T; Kanda T; Hirota S; Ohashi A; Shirai Y; Hatakeyama K
    Br J Cancer; 2004 Jun; 90(11):2059-61. PubMed ID: 15150562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy.
    Eisenberg BL; Judson I
    Ann Surg Oncol; 2004 May; 11(5):465-75. PubMed ID: 15123459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of gastrointestinal stromal tumors with imatinib mesylate: a center-based study of 13 patients].
    Bar-Sela G; Lev LM; Kuten A; Wollner M; Haim N
    Harefuah; 2006 Jan; 145(1):2-7, 80. PubMed ID: 16450715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of patients with gastrointestinal stromal tumour with imatinib mesylate].
    Haugland HK; Jebsen NL; Mannelqvist M; Skar R; Eide J; Øvrebø K; Horn A; Jensen DK; Monge OR; Lilleng PK
    Tidsskr Nor Laegeforen; 2005 Apr; 125(7):868-72. PubMed ID: 15815732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imatinib administration in two patients with liver metastases from GIST and severe jaundice.
    De Pas T; Danesi R; Catania C; Curigliano G; De Braud F;
    Br J Cancer; 2003 Oct; 89(8):1403-4. PubMed ID: 14562006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gastrointestinal stromal tumours.
    Connolly EM; Gaffney E; Reynolds JV
    Br J Surg; 2003 Oct; 90(10):1178-86. PubMed ID: 14515284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imatinib mesylate acts in metastatic or unresectable gastrointestinal stromal tumor by targeting KIT receptors--a review.
    Sawaki A; Yamao K
    Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S44-9. PubMed ID: 15309514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate.
    Rutkowski P; Nowecki Z; Nyckowski P; Dziewirski W; Grzesiakowska U; Nasierowska-Guttmejer A; Krawczyk M; Ruka W
    J Surg Oncol; 2006 Mar; 93(4):304-11. PubMed ID: 16496358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Gastrointestinal stromal tumors (GIST)].
    Reichardt P; Pink D; Mrozek A; Lindner T; Hohenberger P
    Z Gastroenterol; 2004 Apr; 42(4):327-31. PubMed ID: 15095124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Gastrointestinal stromal tumors: a broad clinical spectrum from incidental -discovery to acute gastrointestinal bleeding].
    Siewert E; Tietze L; Maintz C; Geier A; Dietrich CG; Matern S; Gartung C
    Z Gastroenterol; 2004 Mar; 42(3):233-42. PubMed ID: 15022111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of imatinib vary with the types of KIT-mutation in gastrointestinal stromal tumor cell lines.
    Noma K; Naomoto Y; Gunduz M; Matsuoka J; Yamatsuji T; Shirakawa Y; Nobuhisa T; Okawa T; Takaoka M; Tomono Y; Hiroyuki O; Gunduz E; Tanaka N
    Oncol Rep; 2005 Sep; 14(3):645-50. PubMed ID: 16077968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST).
    Nilsson B; Sjölund K; Kindblom LG; Meis-Kindblom JM; Bümming P; Nilsson O; Andersson J; Ahlman H
    Br J Cancer; 2007 Jun; 96(11):1656-8. PubMed ID: 17533389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pilot study of imatinib mesylate (STI571) on gastrointestinal stromal tumors in Japanese patients.
    Sawaki A; Yamao K; Nakamura T; Suzuki T; Okubo K; Hara K; Kawai H; Yamamura Y; Ito S; Mochiduki Y; Ohno R
    J Gastroenterol; 2004; 39(4):329-33. PubMed ID: 15168243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of KIT mutations in sporadic and familial gastrointestinal stromal tumors: therapeutic implications through protein modeling.
    Tarn C; Merkel E; Canutescu AA; Shen W; Skorobogatko Y; Heslin MJ; Eisenberg B; Birbe R; Patchefsky A; Dunbrack R; Arnoletti JP; von Mehren M; Godwin AK
    Clin Cancer Res; 2005 May; 11(10):3668-77. PubMed ID: 15897563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.